Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VIB1116 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| VIB1116 | EXPERIMENTAL | Single dose of VIB1116, SC or IV administration. Multiple doses of VIB1116, SC administration. |
| Placebo | PLACEBO_COMPARATOR | Single dose of Placebo, SC or IV administration. Multiple doses of Placebo, SC administration. |
| Name | Type | Description |
|---|---|---|
| VIB1116 | DRUG | VIB1116 |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Male or female ≥ 18 years of age and ≤ 60 years of age and a body mass index (BMI) \< 30 kg/m² or, in patients who have completed dosing with a vaccine against COVID-19 and are at least 1 month post the last dose, ≤ 65 years of age and BMI \< 35 kg/m\^2 * A diagnosis of one of...
VIB1116 is an investigational small molecule being developed for the treatment of dendritic cell-mediated rheumatic diseases. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with these autoimmune and inflammatory conditions.
VIB1116 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. Amgen is conducting clinical trials to evaluate the safety and efficacy of VIB1116 in patients with dendritic cell-mediated rheumatic diseases.
VIB1116 is in Phase 1 clinical development. A Phase 1 study of the drug has been completed, involving 73 participants. The drug remains investigational and is not yet approved for commercial use. Further clinical trials would be needed to establish its safety and efficacy.
VIB1116 has one completed Phase 1 clinical trial registered as NCT04948099, titled 'A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases.' This randomized, double-blind, placebo-controlled study enrolled 73 participants in the United States and Poland.
VIB1116 is a small molecule designed to target dendritic cell-mediated pathways involved in rheumatic diseases. By modulating the activity of dendritic cells, which play a key role in immune responses, the drug aims to address the underlying inflammatory processes in these conditions.